A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects with Myeloproliferative Disorders.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2011
At a glance
- Drugs XL 019 (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.